In breast cancer, (active), PTEN has been reported to be an essential parameter for responsiveness to trastuzumab treatment, while loss of PTEN rather predicts resistance to trastuzumab in HER2-positive patients (Nagata et al, 2004; Pandolfi, 2004; Fujita et al, 2006). Here, ERBB2 is linked to breast cancer.